Table 1 Baseline characteristics of patients
Clarithromycin group (N = 27) | Placebo group (N = 31) | ||
|---|---|---|---|
Variable | |||
Age (years) | Median (IQR) | 63 (55.0–66.5) | 63 (55.5–66.0) |
Male sex | No. (%) | 20 (74.1%) | 20 (64.5%) |
Type of myeloma | No. (%) | ||
IgA | 3 (11.1%) | 9 (29.0%) | |
IgG | 20 (74.1%) | 17 (54.8%) | |
Light chain | 4 (14.8%) | 5 (16.1%) | |
International staging system | No. (%) | ||
I | 7 (%) (25.9%) | 9 (29.0%) | |
II | 10 (%) (37.0%) | 17 (54.8%) | |
III | 9 (33.1%) | 4 (12.9%) | |
Missing | 1 (3.8%) | 1 (3.2%) | |
Cytogenetic features | No. (%) | ||
Standard risk | 18 (66.7%) | 18 (58.1%) | |
High riska | 6 (22.2%) | 8 (25.8%) | |
Data not available | 3 (11.1%) | 5 (16.1%) | |
WHO performance status | No. (%) | ||
0 | 14 (51.9%) | 17 (54.8%) | |
≥ 1 | 13 (48.1%) | 14 (45.2%) | |
Serum creatinine ≥ 130 µmol/L | No. (%) | 5 (18.5%) | 2 (6.5%) |
Serum LDH ≥ 260 U/L | No. (%) | 1 (3.7%) | 4 (12.9%) |
Serum C-reactive protein ≥ 8 mg/L | No. (%) | 9 (33.3%) | 9 (29.0%) |